The next 15 drugs chosen for Medicare negotiation

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts before the inauguration of President-elect Trump.

The Centers for Medicare and Medicaid Services (CMS) had until Feb. 1 to release the list, but officials said the agency had routinely been ahead of schedule throughout the process.

Coupled with the first 10 drugs that have already been negotiated for by Medicare, the newest selection of drugs represent a third of all Medicare Part D spending. Some of the manufacturers that will have to negotiate this year were also included in last year's talks.

“Today, I’m proud to announce that my Administration has selected the next 15 drugs for Medicare drug price negotiation. The drugs treat conditions such as diabetes and cancer, and seniors across the country rely on them,” President Biden said in a statement.

Novo Nordisk, Merck, Boehringer Ingelheim, Pfizer and Bristol Myers Squibb (parent company of the Celgene Corporation) will all be asked to negotiate with Medicare for a second year in a row. Manufacturers will have until Feb. 28 to sign negotiation agreements.

The conditions treated by these drugs include diabetes, cancer, chronic obstructive pulmonary disease (COPD) and schizophrenia.

Here are the next 15 drugs chosen for Medicare negotiations:

Ozempic; Rybelsus; Wegovy
For treating: Diabetes, obesity
Manufacturer: Novo Nordisk

Trelegy Ellipta
For treating: COPD
Manufacturer: GlaxoSmithKline

Xtandi
For treating: Metastatic castration-resistant prostate cancer
Manufacturer: Astellas Pharma

Pomalyst
For treating: Multiple myeloma
Manufacturer: Celgene Corporation

Ibrance
For treating: Breast cancer
Manufacturer: Pfizer

Ofev
For treating: Idiopathic pulmonary fibrosis
Manufacturer: Boehringer Ingelheim

Linzess
For treating: Irritable bowel syndrome with constipation
Manufacturer: Forest Pharmaceuticals

Calquence
For treating: Mantle cell lymphoma
Manufacturer: AstraZeneca

Austedo; Austedo XR
For treating: Chorea associated with Huntington’s disease, tardive dyskinesia
Manufacturer: Teva Pharmaceuticals

Breo Ellipta
For treating: Airflow obstruction and for reducing exacerbations in COPD patients
Manufacturer: GlaxoSmithKline

Tradjenta
For treating: Type 2 diabetes mellitus
Manufacturer: Boehringer Ingelheim

Xifaxan
For treating: Travelers’ diarrhea caused by E. coli
Manufacturer: Salix Pharmaceuticals

Vraylar
For treating: Schizophrenia, manic episodes associated with bipolar 1 disorder
Manufacturer: Actavis

Janumet; Janumet XR
For treating: Type 2 diabetes mellitus
Manufacturer: Merck

Otezla
For treating: Psoriatic arthritis
Manufacturer: Celgene Corporation

Topics

Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications

The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that go into effect in 2027.
CNBC - 5h
Medicare to Negotiate Lower Prices for Weight-Loss Drugs

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.
The New York Times - 8h
Medicare announces weight-loss drugs, including Ozempic, will be up for price negotiations

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, which includes Ozempic.
NBC News - 7h
Ozempic, Wegovy on list for Medicare drug price negotiations

The hugely popular medications Ozempic and Wegovy, used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.
CBS News - 8h
CMS to seek Medicare negotiations on Ozempic price

The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare negotiation. CMS listed Ozempic, Rybelsus and Wegovy — all forms of semaglutide ...
The Hill - 8h
Biden administration picks 15 more drugs for Medicare negotiation

The Centers for Medicare and Medicaid Services (CMS) has selected 15 more drugs for Medicare price negotiation, announcing the selection two weeks ahead of schedule. Administration officials did ...
The Hill - 9h
Johnson & Johnson makes $15 billion bet on mental-health drugs

Pharma giant Johnson & Johnson is buying Intra-Cellular Therapies, eying sales growth above analysts’ expectations through 2029.
MarketWatch - 4d
Tiger Woods chosen for PGA Tour 2K25 cover: 15-time major champion is featured player in new golf video game

Woods will be featured on all three covers of the video game series' latest release
CBS Sports - 4d
Weight-loss drugs like Ozempic may be up for Medicare price negotiations — will Trump support it?

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face an uncertain future in the incoming Trump administration.
NBC News - Jan. 9